Postmenopausal Osteoporosis Treatment Market Size - By Drug Type (Bisphosphonates, Hormone Replacement Therapy (HRT)), Route of Administration, Distribution Channel, Global Forecast (2023-2032)

Postmenopausal Osteoporosis Treatment Market Size - By Drug Type (Bisphosphonates, Hormone Replacement Therapy (HRT)), Route of Administration, Distribution Channel, Global Forecast (2023-2032)

Postmenopausal Osteoporosis Treatment Market Size

Postmenopausal Osteoporosis Treatment Market size accounted for around USD 7.6 billion in 2022 and is expected to reach USD 11.6 billion by 2032 due to the increasing adoption of highly efficient treatments for postmenopausal osteoporosis. This expansion is further accelerated by changing lifestyles and the growing elderly population.
 

The expanding older demographic, which is more vulnerable is expected to opt for such drugs or medication. For instance, the World Health Organization (WHO) October 2021 reported that the global population aged 60 and above will increase from 1 billion in 2020 to 1.4 billion by 2030 and 2.1 billion by 2050. Postmenopausal osteoporosis treatment refers to the medical interventions and strategies used to manage and reduce the risk of osteoporosis in postmenopausal women. They are at a higher risk of developing osteoporosis because the decline in estrogenic levels during menopause that can accelerate bone loss.
 

COVID-19 Impact

The COVID-19 pandemic has had far-reaching effects on healthcare and medical research, including some moderately positive outcomes in the context of postmenopausal osteoporosis treatment. One notable development is the increased focus on telemedicine and remote healthcare services. The pandemic necessitated a shift toward virtual consultations and telehealth solutions, making it more convenient for postmenopausal women to access healthcare and receive guidance on osteoporosis management.
 

Postmenopausal Osteoporosis Treatment Market Trends

• The postmenopausal osteoporosis treatment landscape is poised for expansion, primarily fueled by increased research and development efforts within the domain of research institutes and pharmaceutical industry players. For instance, in August 2022, Lupin Limited secured an exclusive licensing partnership with Japanese firm I’rom Group Co. Ltd (I’rom) for the clinical evaluation of biosimilar Denosumab in Japan. Denosumab is prescribed for various conditions, including osteoporosis in postmenopausal women at high fracture risk and skeletal-related event prevention in patients with solid tumor bone metastases. Under this agreement, Lupin will gain multiple milestone payments. This collaboration enhanced the Lupin's access to cutting-edge biological therapies with the capacity to transform healthcare.
   

Furthermore, sedentary lifestyles, poor dietary habits impacting menstrual cycles, and a rising aging population are elevating the risk of postmenopausal osteoporosis.
 

• The osteoporosis drugs market faces significant challenges in the form of patent expiration and the loss of exclusive rights. When a branded drug loses its patent protection, it experiences a substantial drop in revenue, often reaching around 35-40% in the initial year.
   
• Although, the affordability of generic alternatives leads to increased consumption, but the generic drugs typically cannot surpass the overall sales of the branded version.
   

Postmenopausal Osteoporosis Treatment Market Analysis

Based on drug type, the market is segmented into bisphosphonates, hormone replacement therapy (HRT), parathyroid hormone, estrogen receptor modulators and other drug type. Bisphosphonates accounted for the largest market share of 38.9% in 2022.
 

• Bisphosphonates are the primary treatment choice for osteoporosis. These medications effectively treat bone loss by reducing osteoclast activity and enhancing bone density and structure. Moreover, the introduction of more effective products is driving market expansion. Notable drugs in this category include Actonel (risedronate) and Fosamax (alendronate), prescribed for daily and monthly use, respectively.
   

Based on route of administration, the postmenopausal osteoporosis treatment market is classified into oral parenteral, transdermal, and nasal. The oral segment accounted for the largest share 47.5 % in 2022.
 

• Oral medications have proven to be an effective option in treating the condition with precise dosage, cost-effective drug and ease of use, making them a preferred choice among patients and healthcare providers.
   
• Also, oral medications, especially alendronate (Fosamax), have proven effective in reducing hip fracture risk by 50%.
   

Based on distribution channel, the market is classified into hospital pharmacies, retail pharmacies and online pharmacies. The retail pharmacy segment held the largest share of the total revenue at 44.5%. in 2022.
 

• Patients are increasingly attracted to retail pharmacies for their convenience and extended treatment durations.
   
• Additionally, retail pharmacies have strengthened partnerships with orthopedic centers, contributing to comprehensive osteoporosis management.

The North America postmenopausal osteoporosis treatment market is expected to grow at a higher rate anticipating its dominance by 2032.
 

• The dominance can be attributed owing to the rising prevalence of postmenopausal osteoporosis among the elderly women population. According to WHO report, osteoporosis account for 30% of caucasian postmenopausal women in the U.S., and 54% exhibit osteopenia. The report also stated that, the prevalence of reduced bone mass escalates with advancing age.
   

Postmenopausal Osteoporosis Treatment Market Share

The key leaders operating in this market have established themselves through innovation, product quality, and a strong market presence. Amgen, Eli Lilly & Company, and Pfizer Inc. account nearly 45% - 50% of the market share. These key industry leaders provide a potential treatment and drug option for postmenopausal osteoporosis. Their offerings comprises a highly effective range of pharmaceuticals, including biosimilars and hormone replacement therapy drugs, which are widely acknowledged as the most effective solutions for managing postmenopausal osteoporosis while demonstrating minimal adverse effects.
 

Market players operating in the postmenopausal osteoporosis industry are as mentioned below

• Eli Lilly and Company
• Merck Sharp & Dohme Corp. (Merck & Co., Inc.)
• AbbVie Company (Allergan Pharmaceuticals International Ltd.)
• Amgen Inc.
• Theramex (PAI and Carlyle)
• Sun Pharmaceutical Industries Ltd.
• Pfizer Inc.
• Novartis AG
• Mylan Inc. (Viatris)
• Chugai Pharma China Co., Ltd. (Roche)
   

Postmenopausal Osteoporosis Treatment Industry News

• In June 2023, Pfizer Inc. reintroduced DUAVEE (conjugated estrogens/bazedoxifene), a menopause hormone therapy containing estrogen, to the U.S. market with enhanced packaging. This return comes after a voluntary recall prompted by a packaging issue, which was unrelated to any concerns regarding the product's effectiveness or safety. This reintroduction strategy is expected to resolve the packaging issues as well as generate revenue from its sales.
   
• In February 2023, Sandoz received Biologics License Application (BLA) from US Food and Drug Administration (FDA) for a prospective biosimilar of denosumab (Prolia and Xgeva; Amgen). The product is intended for addressing a wide range of conditions, such as osteoporosis in postmenopausal women and in men with an elevated fracture risk, alongside numerous other medical conditions.
   

The postmenopausal osteoporosis treatment market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 to 2032 for the following segments

Click here to Buy Section of this Report

By Drug type, 2018 – 2032 (USD Million)

• Bisphosphonates
• Hormone replacement therapy (HRT)
• Parathyroid hormone
• Estrogen receptor modulators
• Other drug types

By Route of Administration, 2018 – 2032 (USD Million)

• Oral
• Parenteral
  • Intravenous (IV)
  • Intramuscular
  • Subcutaneous
• Transdermal
• Nasal

By Distribution Channel, 2018 – 2032 (USD Million)

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

The above information is provided for the following regions and countries

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Rest of Middle East & Africa